Status And Outlook For Biopharma R&D With Former Pfizer R&D Head John LaMattina

Recorded on 11/08/24

TD Cowen analyst Steve Scala speaks with former Pfizer R&D Chief John LaMattina to discuss views of the status and outlook for R&D in biopharma industry. New technologies and deeper understanding of biology provide opportunities, but price pressures and some M&A can stifle creativity. We discussed optimal R&D portfolio construction and concluded with observations on where Pfizer R&D stands today.

https://go.td.com/PodcastDisclosure